Gene therapy: Two steps forward, one step back

CMAJ. Canadian Medical Association Journal

Volumn 170, Issue 12, 2004, Pages 1785-1786

  Johnston, Josephine ^a   Baylis, Françoise ^b  

^a HASTINGS CENTER   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT DNA; RETROVIRUS VECTOR;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; CHROMOSOME 11; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DISEASE SEVERITY; FRANCE; GENE THERAPY; GENETIC DISORDER; HEALTH STATUS; HOSPITAL CARE; HUMAN; IMMUNE SYSTEM; LEUKEMIA; LEUKOCYTE; MUTAGENESIS; ONCOGENE; PEDIATRICS; PERINATAL PERIOD; RANDOMIZATION; RECURRENT INFECTION; REGULATORY MECHANISM; REMISSION; RISK FACTOR; SHORT SURVEY; T LYMPHOCYTE; TREATMENT OUTCOME; X CHROMOSOME LINKED DISORDER;

EID: 3042682691     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1031262     Document Type: Short Survey

References (4)

1. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal Tcell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-9.
2. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favoured targets for MLV Integration. Science 2003;300: 1749-51.
3. Orkin SH, Motulsky AG, cochairs. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Bethesda (MD): National Institute of Health. 1995. Available: www.nih.gov/news/panel rep.html (accessed 2004 Apr 07).
4. Baker DE, FDA Center for Biologics Evaluation and Research. Letter to James L. Wilson, Institute for Human Gene Therapy, Philadelphia, Feb. 8, 2002. Available: www.fda.gov/foi/nooh/Wilson.htm (accessed 2004 Apr 07).